The innovative platform will scan for, and ultimately identify, the lead de novo molecules needed to develop drugs to cure diseases having the most significant impact around the world – with an initial focus on finding a cure for the widespread dengue fever.
While other approaches review tens of millions of molecules, Fujitsu and Polarisqb’s platform can review billions. It can not only scan more molecules, but it can do so much quicker than any other drug discovery platform on the market. Fujitsu’s quantum-inspired Digital Annealer technology is 10,000 times faster than any other solution – cutting the time taken to identify lead molecules and reach the first stages of drug development from 2-4 years to just eight months.
Once lead molecules are identified, Polarisqb’s proprietary machine-learning algorithm and QM/MM simulations then quickly assess whether the molecules possess all the properties that a drug requires to be brought to market. Outbreaks such as the coronavirus highlight the growing need for faster processes to find a cure, and this platform is designed to support pharmaceutical companies to react effectively and at pace.
Patrick Stephenson, Director of Innovation & Healthcare at Fujitsu UK, said: “Fujitsu’s quantum-inspired Digital Annealer is a truly pioneering technology, and I am excited about the impact it will have on improving the drug discovery process together with our partner Polarisqb. We are looking forward to scaling this platform to tackle many more diseases in the future, enabling new drugs to be brought to patients faster and more cost-effectively.”
Dr Shahar Keinan, CEO at Polarisqb (a Cloud Pharmaceuticals spin-out), said: "Polarisqb is excited to be co-creating this novel platform that can revolutionise drug design. We believe drug development has reached an inflection point, and that leveraging advances in quantum-inspired computing will dramatically increase the speed of computation and diversity of candidate molecules, answering clear needs in the market."
The current pilot is identifying the right molecules necessary to develop a cure for dengue fever, a wide-spread disease with 100 million infections and 22,000 deaths every year. There is still no cure for dengue fever that is suitable for all people affected, so Fujitsu and Polarisqb prioritised this important target for the pilot of their joint drug discovery platform.
The new lead molecules for a dengue fever drug are estimated to be made available for partners to take through to the next stage in the drug discovery process by May 2020. In parallel, the two companies are exploring the next disease targets with pharmaceutical partners.
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 132,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.0 trillion yen (US $36 billion) for the fiscal year ended March 31, 2019. For more information, please see www.fujitsu.com.
Fujitsu UK & Ireland employs over 9,000 people. We promote a Human Centric Intelligent Society, in which innovation is driven by the integration of people, information and infrastructure. We are committed to Digital Co-creation, blending business expertise with digital technology and creating new value with ecosystem partners and customers. We enable our customers to digitally transform with connected technology services, focused on Artificial Intelligence, the Internet of Things, and Cloud - all underpinned by Security. Our customers cover both the public and private sectors, including retail, financial services, transport, manufacturing, government and defence. For more information please see http://uk.fujitsu.com
Conrad ArnavutianAddress: Harvard
Phone: +44 (0) 20 7861 2800
Phone: + 44 (0)20 3949 2205
Date: 16 March, 2020
Share this page